Literature DB >> 24132627

High expression of interleukin-22 and its receptor predicts poor prognosis in pancreatic ductal adenocarcinoma.

Zhang Wen1, Quan Liao, Jianguo Zhao, Ya Hu, Lei You, Zhaohui Lu, Congwei Jia, Yingxin Wei, Yupei Zhao.   

Abstract

BACKGROUND: The cytokine interleukin-22 (IL-22) and its receptor are present in the tumor microenvironment. Their function in pancreatic ductal adenocarcinoma (PDAC) remains largely unknown. The goal of the present study was to measure the expression of IL-22 and IL-22R in PDAC and assess their relationship with clinicopathological features and prognosis.
METHODS: The expression of IL-22 and IL-22R was evaluated by immunohistochemistry in PDAC tissues from 57 patients and by Western blotting in six tumors and adjacent nontumor tissues. A statistical analysis was conducted to assess the relationship between levels of expression, clinicopathological factors, and overall survival. In addition, the relationship between the expression of IL-22 and IL-22R and invasion was assessed by Western blotting and transwell assay with the PDAC cell lines PANC1 and BxPC3.
RESULTS: Positive IL-22 staining was detected in PDAC tissues and adjacent nontumor tissues. Positive IL-22R staining was detected in PDAC cells. High expression of IL-22 and IL-22R correlated significantly with lymph node involvement. IL-22 increased the phosphorylation of signal transducer and activator of transcription3, the expression of matrix metalloproteinase 9, and the invasion in PANC1 and BxPC3 cells in vitro while silencing of IL-22R RNA caused opposite effects. Most importantly, overall survival was significantly poorer in patients with high expression of IL-22 and IL-22R than in those with low expression.
CONCLUSIONS: These findings reveal the positive role of IL-22 and IL-22R in invasion and metastasis in human PDAC. IL-22 and IL-22R may be suitable independent prognostic markers in PDAC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24132627     DOI: 10.1245/s10434-013-3322-x

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  20 in total

1.  IL-22 promotes the migration and invasion of gastric cancer cells via IL-22R1/AKT/MMP-9 signaling.

Authors:  Yinghua Ji; Xiaoyu Yang; Jinsong Li; Zhihong Lu; Xiaorui Li; Jian Yu; Na Li
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

Review 2.  Biological and pathological activities of interleukin-22.

Authors:  Mirna Perusina Lanfranca; Yanwei Lin; Jingyuan Fang; Weiping Zou; Timothy Frankel
Journal:  J Mol Med (Berl)       Date:  2016-02-29       Impact factor: 4.599

Review 3.  Interleukin-22 and Cyclosporine in Aggressive Cutaneous Squamous Cell Carcinoma.

Authors:  Alexis L Santana; Diane Felsen; John A Carucci
Journal:  Dermatol Clin       Date:  2017-01       Impact factor: 3.478

4.  Interleukin 22 Signaling Regulates Acinar Cell Plasticity to Promote Pancreatic Tumor Development in Mice.

Authors:  Mirna Perusina Lanfranca; Yaqing Zhang; Alexander Girgis; Samantha Kasselman; Jenny Lazarus; Illona Kryczek; Lawrence Delrosario; Andrew Rhim; Lada Koneva; Maureen Sartor; Lei Sun; Christopher Halbrook; Hari Nathan; Jiaqi Shi; Howard C Crawford; Marina Pasca di Magliano; Weiping Zou; Timothy L Frankel
Journal:  Gastroenterology       Date:  2019-12-14       Impact factor: 22.682

5.  Interleukin-22 secreted by cancer-associated fibroblasts regulates the proliferation and metastasis of lung cancer cells via the PI3K-Akt-mTOR signaling pathway.

Authors:  Hongbo Li; Quan Zhang; Qi Wu; Yayun Cui; Hong Zhu; Mingming Fang; Xifa Zhou; Zhiqiang Sun; Jingping Yu
Journal:  Am J Transl Res       Date:  2019-07-15       Impact factor: 4.060

Review 6.  The IL-20 subfamily of cytokines--from host defence to tissue homeostasis.

Authors:  Sascha Rutz; Xiaoting Wang; Wenjun Ouyang
Journal:  Nat Rev Immunol       Date:  2014-12       Impact factor: 53.106

Review 7.  Interleukin-22: immunobiology and pathology.

Authors:  Jarrod A Dudakov; Alan M Hanash; Marcel R M van den Brink
Journal:  Annu Rev Immunol       Date:  2015-02-11       Impact factor: 28.527

8.  Cyclosporine A immunosuppression drives catastrophic squamous cell carcinoma through IL-22.

Authors:  Melody Abikhair; Hiroshi Mitsui; Valerie Yanofsky; Nazanin Roudiani; Channa Ovits; Teddy Bryan; Tatiana M Oberyszyn; Kathleen L Tober; Juana Gonzalez; James G Krueger; Diane Felsen; John A Carucci
Journal:  JCI Insight       Date:  2016-06-02

9.  IL22/IL-22R pathway induces cell survival in human glioblastoma cells.

Authors:  Hussein Akil; Amazigh Abbaci; Fabrice Lalloué; Barbara Bessette; Léa M M Costes; Linda Domballe; Sandrine Charreau; Karline Guilloteau; Lucie Karayan-Tapon; François-Xavier Bernard; Franck Morel; Marie-Odile Jauberteau; Jean-Claude Lecron
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

10.  IL-22 produced by cancer-associated fibroblasts promotes gastric cancer cell invasion via STAT3 and ERK signaling.

Authors:  H Fukui; X Zhang; C Sun; K Hara; S Kikuchi; T Yamasaki; T Kondo; T Tomita; T Oshima; J Watari; J Imura; T Fujimori; M Sasako; H Miwa
Journal:  Br J Cancer       Date:  2014-06-17       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.